ClinicalTrials.gg
TerminatedNCT01071200Luveris in ARTUpdated Dec 27, 2013Results posted

Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

A Phase 3 interventional study of Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) and r-hFSH in Reproductive Techniques, Assisted, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The present study was designed to investigate, in hyporesponder subjects, that required in a previous assisted reproductive technologies (ART) cycle follicle stimulating hormone (FSH) >3500 International Unit (IU), the possibility to decrease through recombinant human luteinizing hormone (r-hLH) supplementation, the FSH amount per oocytes retrieved and in the mean time to improve the overall cycle outcome.

Read the detailed description

Recombinant human follicle stimulating hormone (r-hFSH), which totally lacks LH activity, is widely used to induce multiple follicle development in women under pituitary desensitization, in order to submit them to treatment with assisted reproduction techniques (ART). Clinical experience from hypogonadotropic-hypogonadic women suggests that while FSH alone is sufficient to induce follicle development, LH plays a significant part in final follicle maturation, estrogen synthesis and optimal endometrium growth.

This was a phase III, multicentre, randomized, open-label comparative study to evaluate if the addition of r-hLH (Luveris) in a 2:1 ratio to FSH from day 8 of ovarian stimulation is able to decrease the total FSH dose and to improve cycle outcome in 250 infertile women undergoing ART, who required high FSH dose in a previous cycle (≥ 3500 IU). Subjects who have met all the inclusion criteria, achieved pituitary desensitization and started controlled ovarian hyperstimulation (COH) treatment with FSH, on stimulation day 8 (S8) received an identification number and will be allocated to one of the two following arms:

Arm : FSH + r-hLH (2:1 ratio of FSH:r-hLH), Arm : FSH alone. Treatment with Luveris was commenced on day 8 (S8) and continued until injection of hCG or cancellation of the treatment cycle.

Monitoring of stimulation, FSH dose escalation, criteria for injection of hCG, ovum pick up, embryo transfer and pregnancy confirmation took place according to standard management practice. The in-vitro fertilization (IVF) or intracytosolic sperm injection (ICSI) procedure, including luteal phase support, was performed according to each centres' normal procedures.

The subjects were followed up and the treatment outcome (menstruation or pregnancy) was recorded. The delivery outcome for any pregnant subjects was recorded in the Case Report Form (CRF).

Information on the delivery outcome for each pregnancy was collected. Information on adverse events was collected during the study period.

OBJECTIVES

The primary objective of the study was:

To determine whether the addition of r-hLH (Luveris) from day 8 of ovarian stimulation reduces the FSH dose needed to obtain/retrieve each oocyte.

The secondary objectives of the study were:

  • To determine whether the addition of Luveris to FSH at day 8 of ovarian stimulation improves cycle outcome based on secondary endpoints
  • To determine the safety of Luveris in this indication
02

Conditions studied

  • Reproductive Techniques, Assisted

Keywords

  • Reproductive Techniques, Assisted
  • Recombinant human follicle stimulating hormone (r-hFSH)
  • Recombinant leutinizing hormone (r-hLH)
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-menopausal infertile woman, aged 18 to 40 years inclusive, who wishes to conceive
  • Regular, spontaneous menstrual cycle of 25-35 days
  • (BMI) ≤ 28
  • FSH ≤ 10 IU/L (follicular phase, days 2-5)
  • Prolactin (PRL) within the normal ranges
  • Evidence of both ovaries by ultrasound scan
  • Women undergoing IVF-Embryo Transfer (ET) or ICSI, down regulated with Gonadotropin releasing hormone analogues (GnRHa) (daily dose) under controlled ovarian hyperstimulation (COH) with FSH
  • Washout > 90 days from last dose of clomiphene or gonadotrophin, before ongoing COH cycle
  • Only one previous IVF-ET or ICSI cycle (in the last 9 months preceding the ongoing COH cycle) resulted in a hypo-response properly documented (from 6 to 12 oocytes with a total FSH dose ≥ 4000 IU)
  • Negative pregnancy hCG test (urine or blood sample) before the ongoing COH cycles
  • Willing and able to comply with the protocol for the duration of the study
  • Written before applying any procedure related to the study protocol, which is not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time, without prejudice on their future medical care

Exclusion criteria

Exclusion Criteria:

  • Oligo/Anovulatory cycles (World Health Organization [WHO] I and II)
  • Male partner azoospermia (assessed within the last 12 months)
  • Follicular phase (day 2-5) FSH > 10 IU/L even if only once observed in the medical history
  • Abnormal cervical cytology (assessed within the last 12 months)
  • History of unexplained gynecologic hemorrhage
  • Any to pregnancy
  • Known allergy to gonadotrophin
  • Any systemic disease (e.g. insulin-dependent diabetes mellitus, epilepsy, serious migraine, intermittent purpura, hepatic, renal or cardiovascular disease, serious corticoid-dependent asthma) which constitutes a contraindication to gonadotropin use
  • Any medical condition which, according to the investigator's judgement, may affect the absorption, distribution, metabolism or excretion of the drug. In case of doubt, inclusion of the subject in question should be discussed with the Medical Responsible of Serono
  • Known (HIV) positivity
  • Any substance abuse or history of drugs or alcohol abuse within the past 5 years
  • Prior inclusion in the present study or simultaneous inclusion in a clinical study of another drug
  • Refusal or inability to comply with the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    A

    Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)

    Drug: Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)

  • Active comparator
    B

    Subjects treated with r-hFSH alone

    Drug: r-hFSH

Interventions

  • DrugRecombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)

    Drug page: Follitropin alfa

    One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.

    Also known as: r-hLH, r-hFSH

  • Drugr-hFSH

    One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.

06

What researchers measure

Primary outcomes

  1. Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes

    Time frame: Baseline (Stimulation day 8 [S8]) until hCG day

Secondary outcomes

  1. Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose

    Time frame: Baseline (S8) until hCG day

  2. Mean Number of Ovarian Stimulation Days

    Time frame: Baseline (S8) until hCG day

  3. Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day

    Time frame: Baseline (S8) and hCG day

  4. Mean Total Number of Retrieved Oocytes

    Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

    Time frame: 34-36 hours post-hCG (OPU)

  5. Mean Number of Mature Oocytes (Metaphase II)

    Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.

    Time frame: 34-36 hours post-hCG (OPU)

  6. Fertilization Rate

    Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).

    Time frame: 12-18 day post-hCG and/or Week 7

  7. Number of Obtained Embryos

    Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.

    Time frame: Day 3 post-hCG (Embryo transfer [ET])

  8. Number of Transferred Embryos

    Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.

    Time frame: Day 3 post-hCG (ET)

  9. Percentage of Participants With Pregnancy

    Time frame: 12-18 day post-hCG and/or Week 7

  10. Percentage of Participants With Clinical Pregnancy

    Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

    Time frame: 12-18 day post-hCG and/or Week 7

  11. Percentage of Participants With Implantation

    Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.

    Time frame: 12-18 day post-hCG and/or Week 7

  12. Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)

    OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.

    Time frame: Baseline (S8) until 12-18 day post-hCG and/or Week 7

  13. Number of Cycles Cancelled Due to Risk of OHSS

    OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.

    Time frame: Baseline (S8) until 12-18 day post-hCG and/or Week 7

07

Results

Posted Aug 14, 2012

Participant flow

Participant flow — Overall Study
MilestoneFSH + rhLHFollicle-stimulating Hormone (FSH)
Started6766
Completed6063
Not completed73
Withdrew: Lack of ovarian response11
Withdrew: No fertilization40
Withdrew: No oocytes retrieved11
Withdrew: Ovarian hyper stimulation syndrome10
Withdrew: No viable embryos01

Outcome measures

PrimaryTotal Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes
Time frame:
Baseline (Stimulation day 8 [S8]) until hCG day
Reported as:
Mean · IU
Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes
IUFSH + rhLHFollicle-stimulating Hormone (FSH)
Baseline (S8)904.6 ± 1068.1703.3 ± 924.5
Baseline (S8) until hCG day388.5 ± 631.3318.5 ± 534.0
SecondaryMean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose
Time frame:
Baseline (S8) until hCG day
Reported as:
Mean · IU
Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose
IUFSH + rhLHFollicle-stimulating Hormone (FSH)
Total FSH dose1434.0 ± 678.11595.0 ± 796.4
Total r-hLH dose575.9 ± 273.00 ± 0
SecondaryMean Number of Ovarian Stimulation Days
Time frame:
Baseline (S8) until hCG day
Reported as:
Mean · Days
Mean Number of Ovarian Stimulation Days
DaysFSH + rhLHFollicle-stimulating Hormone (FSH)
Mean Number of Ovarian Stimulation Days4.6 (2.0 to 10.0)4.8 (1.0 to 9.0)
SecondaryChange From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day
Time frame:
Baseline (S8) and hCG day
Reported as:
Mean · picogram/milliter (pg/mL)
Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day
picogram/milliter (pg/mL)FSH + rhLHFollicle-stimulating Hormone (FSH)
Baseline (n = 59,59)516.1 ± 353.6518.9 ± 334.2
Change at hCG day (n = 40,47)1391.6 ± 743.41179.9 ± 746.5
Statistical analysis
  • FSH + rhLH vs Follicle-stimulating Hormone (FSH) · Wilcoxon two sample test · p = 0.07
SecondaryMean Total Number of Retrieved Oocytes

Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

Time frame:
34-36 hours post-hCG (OPU)
Reported as:
Mean · oocytes
Mean Total Number of Retrieved Oocytes
oocytesFSH + rhLHFollicle-stimulating Hormone (FSH)
Mean Total Number of Retrieved Oocytes7.0 ± 4.67.8 ± 3.9
SecondaryMean Number of Mature Oocytes (Metaphase II)

Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.

Time frame:
34-36 hours post-hCG (OPU)
Reported as:
Mean · Metaphase II Oocytes
Mean Number of Mature Oocytes (Metaphase II)
Metaphase II OocytesFSH + rhLHFollicle-stimulating Hormone (FSH)
Mean Number of Mature Oocytes (Metaphase II)5.1 ± 3.75.7 ± 3.2
SecondaryFertilization Rate

Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).

Time frame:
12-18 day post-hCG and/or Week 7
Reported as:
Mean · ratio
Fertilization Rate
ratioFSH + rhLHFollicle-stimulating Hormone (FSH)
Fertilization Rate0.85 ± 0.290.89 ± 0.20
SecondaryNumber of Obtained Embryos

Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.

Time frame:
Day 3 post-hCG (Embryo transfer [ET])
Reported as:
Number · embryos
Number of Obtained Embryos
embryosFSH + rhLHFollicle-stimulating Hormone (FSH)
Number of Obtained Embryos142158
SecondaryNumber of Transferred Embryos

Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.

Time frame:
Day 3 post-hCG (ET)
Reported as:
Number · embryos
Number of Transferred Embryos
embryosFSH + rhLHFollicle-stimulating Hormone (FSH)
Number of Transferred Embryos6063
SecondaryPercentage of Participants With Pregnancy
Time frame:
12-18 day post-hCG and/or Week 7
Reported as:
Number · percentage of participants
Percentage of Participants With Pregnancy
percentage of participantsFSH + rhLHFollicle-stimulating Hormone (FSH)
Percentage of Participants With Pregnancy29.930.8
SecondaryPercentage of Participants With Clinical Pregnancy

Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

Time frame:
12-18 day post-hCG and/or Week 7
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Pregnancy
percentage of participantsFSH + rhLHFollicle-stimulating Hormone (FSH)
Percentage of Participants With Clinical Pregnancy23.918.5
SecondaryPercentage of Participants With Implantation

Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.

Time frame:
12-18 day post-hCG and/or Week 7
Reported as:
Number · percentage of participants
Percentage of Participants With Implantation
percentage of participantsFSH + rhLHFollicle-stimulating Hormone (FSH)
Percentage of Participants With Implantation13.3811.39
SecondaryNumber of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)

OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.

Time frame:
Baseline (S8) until 12-18 day post-hCG and/or Week 7
Reported as:
Number · participants
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
participantsFSH + rhLHFollicle-stimulating Hormone (FSH)
Mild OHSS00
Moderate OHSS10
Severe OHSS00
SecondaryNumber of Cycles Cancelled Due to Risk of OHSS

OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.

Time frame:
Baseline (S8) until 12-18 day post-hCG and/or Week 7
Reported as:
Number · cycles
Number of Cycles Cancelled Due to Risk of OHSS
cyclesFSH + rhLHFollicle-stimulating Hormone (FSH)
Number of Cycles Cancelled Due to Risk of OHSS10

Adverse events

Collected over AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 12-18 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSH + rhLH—1/67 (1.5%)2/67 (3%)
Follicle-stimulating Hormone (FSH)—2/66 (3%)0/66 (0%)
Most frequent serious events
Most frequent serious events
EventFSH + rhLHFollicle-stimulating Hormone (FSH)
Left ectopic pregnancyGeneral disorders0/671/66
Renal colicGeneral disorders0/671/66
CerclageGeneral disorders1/670/66
Most frequent other events
Most frequent other events
EventFSH + rhLHFollicle-stimulating Hormone (FSH)
Ovarian Hyper Stimulation SyndromeGeneral disorders1/670/66
Urticaria post intake of food (fish)General disorders1/670/66

Baseline characteristics

Age, Continuous
Age, Continuous(years)FSH + rhLHFollicle-stimulating Hormone (FSH)Total
Mean35.6 ± 2.935.0 ± 3.835.3 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)FSH + rhLHFollicle-stimulating Hormone (FSH)Total
Female6766133
Male000
08

Study locations

1 site
  • Merck Serono S.p.A.
    Roma, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2010
First posted
Feb 19, 2010
Start
Mar 2005
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Aug 14, 2012
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01071200
Collaborators
Merck Serono S.P.A., Italy
Responsible party
Sponsor
First posted
Feb 19, 2010
Start date
Mar 2005
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Aug 14, 2012
Last update
Dec 27, 2013

Study contacts

Salvatore Longobardi
study director · Merck Serono S.P.A., Italy
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion